This shows a 16 weeks post-conception human fetal lung. The branching airway tree is surrounded by bands of developing smooth muscle (green), which also labels the developing vasculature. The epithelial progenitor cells (co expressing SFTPC in white and NOTUM in red) are initiating the process of alveolar epithelial development. Image supplied by co-author Emma Rawlins (University of Cambridge), Image credit Dr Kyungtae Lim.

Biggest leap in identified lung health genes paves way for personalised risk score

Monday, 13 March 2023

Over 500 new genes have been linked to lung function for the first time, allowing scientists to better understand lung disease.

The study, led by the University of Nottingham and the University of Leicester, is the largest and most diverse study of its kind. The findings pave the way for potential new treatments to tackle conditions such as COPD and asthma, and highlight existing drugs that could potentially be repurposed at speed.

Published in the journal Nature Genetics, the study analyses genome data from 580,869 participants worldwide to build the most confident picture yet of how our genes affect our lung health.

Lung function tests analyse how well the lungs move air in and out of the body. In conditions such as asthma and COPD this is made more difficult by narrowing of the airways. Chronic respiratory disease, such as COPD, is the third leading cause of death globally.

Establishing which genes are involved in lung function is important as it is these genes that encode the proteins that medicines target to prevent or treat disease. Using a new approach that brings together big data relating to genetic variation, lung health and the influences of genetic variation on gene function, this study has been able to identify 559 new genes implicated in lung function with greater confidence than ever before.

Inclusion of people from diverse backgrounds in genetics research is important to make sure that all groups of people benefit from the advances in prevention and treatment that such research can bring.
Professor Ian Hall, Director of the Nottingham Biomedical Research Centre

It is a huge boost to scientists as they seek to understand which medicines may help improve lung health, and also which medicines might make lung health worse.

Principal Investigator on the study, Professor Martin Tobin from the University of Leicester Department of Population Health Sciences, said: “This is a big leap in terms of the size and the ethnic diversity of the populations that we've been able to study before and it's a huge step in the number of associated genetic variants that we've discovered.

“Our genetic research findings can be used to generate individual risk scores that could personalise medicine. At this stage the risk scores we developed form important tools for further research, but in the future these could help to select which drugs might be most effective for individual patients, and which drugs should be avoided.”

The study combined genomic information from multiple research studies worldwide as part of the SpiroMeta consortium and the CHARGE consortium. This provided the researchers with the most ethnically diverse population for this type of study to make their analysis. The study was funded by Wellcome and supported by the National Institute of Health and Care Research (NIHR) Biomedical Research Centres in Leicester and Nottingham.

The University of Nottingham lead Professor Ian Hall commented: “Inclusion of people from diverse backgrounds in genetics research is important to make sure that all groups of people benefit from the advances in prevention and treatment that such research can bring. At present though, the majority of people in genetic studies are from white backgrounds. In the future, we urgently need more studies in different ethnic groups to provide the necessary sample sizes to really take the field forward.”

The discoveries come as the researchers begin an £8.8 million project funded by Wellcome aiming to identify drug targets and accelerate the process of developing new treatments for lung conditions by combining expertise in data science, genomics and cutting-edge laboratory techniques in a ‘one-stop shop’.

Professor Tobin adds: “Bringing teams from the Universities of Leicester, Nottingham and Cambridge with expertise spanning genomics, data science and cell biology into a single project means that we can speed up the steps leading to new treatments. This Wellcome funding also means that we will be able to improve the diversity of genomic studies in the UK, such as the EXCEED study, and boost genomic studies of lung disease in under-served populations worldwide.”

The paper, titled: ‘Multi-ancestry genome-wide association analyses improve resolution of genes and pathways influencing lung function and chronic obstructive pulmonary disease risk’ is published in Nature Genetics, DOI: 10.1038/s41588-023-01314-0, and can be read in full here:

Story credits

For more information, contact Professor Ian Hall at or call +44 (0) 115 823 0019.

Adam Mallaby - Media Relations Manager for the Faculty of Medicine and Health Sciences (Maternity Cover)
Phone: 0115 748 5719

Notes to editors:

About the University of Nottingham

Ranked 32 in Europe and 16th in the UK by the QS World University Rankings: Europe 2024, the University of Nottingham is a founding member of the Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.

Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 – the third time it has been given the honour since 2018 – and by the Daily Mail University Guide 2024.

The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.

The university is a major employer and industry partner - locally and globally - and our graduates are the second most targeted by the UK's top employers, according to The Graduate Market in 2022 report by High Fliers Research.

We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.

More news…

Media Relations - External Relations

The University of Nottingham
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798